Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
- Conditions
- Second Line Treatment of Gastric Cancer
- Interventions
- Registration Number
- NCT05669807
- Lead Sponsor
- Zhejiang Cancer Hospital
- Brief Summary
This study is a multicenter, open, and randomized clinical phase II exploratory study. The "pick the winner" study design is used to determine and select which chemotherapy drug (irinotecan vs. albumin plus paclitaxel) is more effective in the second-line treatment of advanced gastric cancer, and it is more hopeful to carry out the follow-up phase III study in the second-line treatment of advanced gastric cancer (karelizumab+chemotherapy vs. chemotherapy). The study plans to include 184 patients with advanced gastric cancer who have received first-line platinum+fluorouracil progression, randomly use albumin paclitaxel+carrelizumab or irinotecan+carrelizumab second-line therapy, and observe the objective effective rate (ORR), total survival time (OS), progression free survival time (PFS), treatment related adverse reactions, quality of life and other clinical indicators after receiving the above treatment, Then determine the second line scheme which is more advantageous.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 184
- Age: 18-75
- ECOG score: 0 or 1
- Unresectable advanced or recurrent gastric cancer/gastroesophageal junction cancer
- histologically proven adenocarcinoma
- Received chemotherapy based on platinum and fluorouracil within 12 months
- Patients not previously treated with paclitaxel or irinotecan
- Liver function: total bilirubin, ALT and AST<1.5 × ULN (Normal Value upper limit)
- Renal function: Cr<1.5 × ULN and creatinine clearance ≥ 40 ml/min
- Echocardiography or radionuclide cardiac function test, LVEF ≥ 50%
- Expected survival ≥ 3 months
- Sign the informed consent form
- Patients who have received irinotecan or paclitaxel chemotherapy in the past
- ECOG PS score:>2
- Advanced gastric cancer patients with extensive and severe peritoneal metastasis
- Patients with severe liver and kidney insufficiency or cardiac insufficiency
- HIV positive, active hepatitis B or C, active pulmonary tuberculosis
- Patients with active autoimmune diseases, including lupus erythematosus, rheumatoid arthritis, rheumatoid arthritis, etc
- Patients known to be allergic to any of the study drugs
- Pregnant or lactating female patients
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A: Camrelizumab+Albumin-bound paclitaxel Albumin-Bound Paclitaxel Camrelizumab 200mg d1, one cycle every 14 days on the first day; albumin binding paclitaxel: 100 mg/m2, one cycle every 28 days on the first, eighth and fifteenth days B: Camrelizumab+Irinotecan Camrelizumab Camrelizumab 200mg d1, the first day, every 14 days as a cycle Irinotecan: 180 mg/m2, the first day, every 14 days as a cycle A: Camrelizumab+Albumin-bound paclitaxel Camrelizumab Camrelizumab 200mg d1, one cycle every 14 days on the first day; albumin binding paclitaxel: 100 mg/m2, one cycle every 28 days on the first, eighth and fifteenth days B: Camrelizumab+Irinotecan Irinotecan Camrelizumab 200mg d1, the first day, every 14 days as a cycle Irinotecan: 180 mg/m2, the first day, every 14 days as a cycle
- Primary Outcome Measures
Name Time Method Objective Response Rate up to 12 weeks CR+PR
- Secondary Outcome Measures
Name Time Method Progression-free Survival From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months Time from random start of treatment to death or tumor progression due to any reason
Treatment related adverse reactions 24 months Evaluation according to CTC 4.0
Overall Survival From date of randomization until the date of date of death from any cause, assessed up to 24 months Time from random start of treatment to death from any cause
Quality of life assessment 24 months according to EORTC C30